Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
May 20, 2021
Q1 2021 Financial Results
June 20, 2021
AGM – Record date
2020 Universal Registration Document
Valneva has published its 2020 Universal Registration Document.
View MoreContact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com